Loading...
Docoh

Jemapete Christopher J

Filed: 18 Mar 21, 2:05pm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

SCHEDULE 13D/A

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

 

GENE BIOTHERAPEUTICS, INC.

(Name of Issuer)

 

Common Stock

(Title of Class of Securities)

 

86767104 1

(CUSIP Number)

 

Christopher J. Jemapete

6888 S. Irvington Court

Aurora, CO 80016

(303) 877-3033

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

 

March 16, 2021

(Date of Event which Requires Filing of This Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [_].

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 
 

 

CUSIP No. 86767104 1Schedule 13D/APage 2 of 4 Pages

 

1NAMES OF REPORTING PERSONS
 Christopher J. Jemapete
  
2CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 (a) [  ]
 (b) [  ]
  
3SEC USE ONLY
  
  
4SOURCE OF FUNDS
 PF
  
5CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
 PURSUANT TO ITEMS 2(d) OR 2(e) [_]
  
6CITIZENSHIP OR PLACE OF ORGANIZATION
 United States

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
 
7SOLE VOTING POWER
 4,000,000
  
8

SHARED VOTING POWER

0

  
9SOLE DISPOSITIVE POWER
 4,000,000
  
10

SHARED DISPOSITIVE POWER

0

 

11AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
4,000,000
  
12CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [  ]
  
13PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 27.6% (1)
  
14TYPE OF REPORTING PERSON*
 IN

 

(1)Based on 14,489,399 shares of the issuer’s common stock issued and outstanding as of May 22, 2020, as reported on the issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 28, 2020.

 

 
 

 

CUSIP No. 86767104 1Schedule 13D/APage 3 of 4 Pages

 

Item 1. Security and Issuer.

 

This Amendment No. 1 to Schedule 13D relates to the common stock of Gene Biotherapeutics, Inc., a Delaware corporation (the “Company” or the “Issuer”). The address of the Issuer’s principal executive office is 11230 Sorrento Valley Road, Suite 220, San Diego, California 92122.

 

Item 2. Identity and Background.

 

(a) Christopher J. Jemapete
   
(b) 6888 S. Irvington Court, Aurora, CO 80016
   
(c) Retired
   
(d) During the last five years, Mr. Jemapete has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
   
(e) During the last five years, Mr. Jemapete was not a party to a civil proceeding of a judicial or administrative body of competent jurisdiction, as a result of which proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
   
(f) United States

 

Item 3. Source and Amount of Funds or Other Consideration.

 

Mr. Jemapete purchased an aggregate of 500,000 shares of the issuer’s common stock in a series of transactions effected between March 16, 2021 and March 17, 2021. Mr. Jemapete used his personal funds for these purchases.

 

Item 4. Purpose of Transaction.

 

Mr. Jemapete purchased an aggregate of 500,000 of the issuer’s common stock in a series of transactions effected between March 16, 2021 and March 17, 2021 via open market purchases. These securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

Item 5. Interest in Securities of the Issuer.

 

(a) 4,000,000 shares, or approximately 27.6% (based on 14,489,399 shares of the issuer’s common stock issued and outstanding as of May 22, 2020, as reported on the issuer’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 28, 2020).

 

(b)Sole voting power: 4,000,000 shares
 Shared voting power: 0 shares
 Sole dispositive power: 4,000,000 shares
 Shared dispositive power: 0 shares

 

(c) The reporting person effected open market purchases of the following shares of the issuer’s common stock during the past 60 days:

 

Date Aggregate No. of Shares Purchased  Average Price Per Share 
March 16, 2021  20,000  $0.0378 
March 16, 2021  280,000  $0.0400 
March 17, 2021  1,000  $0.0401 
March 17, 2021  500  $0.0402 
March 17, 2021  23,500  $0.0402 
March 17, 2021  20,000  $0.0378 
March 17, 2021  5,000  $0.0404 
March 17, 2021  20,000  $0.0379 
March 17, 2021  5,000  $0.0406 
March 17, 2021  20,000  $0.0381 

 

 
 

 

CUSIP No. 86767104 1Schedule 13D/APage 4 of 4 Pages

 

Date Aggregate No. of Shares Purchased  Average Price Per Share 
March 17, 2021  5,000  $0.0408 
March 17, 2021  20,000  $0.0383 
March 17, 2021  11,000  $0.0410 
March 17, 2021  1,000  $0.0425 
March 17, 2021  8,000  $0.0425 
March 17, 2021  3,116  $0.0425 
March 17, 2021  10,000  $0.0425 
March 17, 2021  5,000  $0.0425 
March 17, 2021  40,000  $0.0425 
March 17, 2021  1,884  $0.0414 

 

(d) Not applicable.

 

(e) Not applicable.

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

 

Not applicable.

 

Item 7. Material to be Filed as Exhibits.

 

None.

 

 
 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 CHRISTOPHER J. JEMAPETE
  
Dated: March 18, 2021/s/ Christopher J. Jemapete